Case: 3:24-cv-00186-WHR-CHG Doc #: 2 Filed: 07/11/24 Page: 1 of 3 PAGEID #: 57

Case MDL No. 3094 Document 232 Filed 07/11/24 Page 1 of 3

UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION

IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION

MDL No. 3094

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO –17)

On February 2, 2024, the Panel transferred 17 civil action(s) to the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. See _F.Supp.3d_ (J.P.M.L. 2024). Since that time, 56 additional action(s) have been transferred to the Eastern District of Pennsylvania. With the consent of that court, all such actions have been assigned to the Honorable Karen S. Marston.

It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Eastern District of Pennsylvania and assigned to Judge Marston.

Pursuant to Rule 7.1 of the <u>Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation</u>, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the Eastern District of Pennsylvania for the reasons stated in the order of February 2, 2024, and, with the consent of that court, assigned to the Honorable Karen S. Marston.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Eastern District of Pennsylvania. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7–day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is pending at this time, the stay is lifted.

Jul 11, 2024

CLERK'S OFFICE
UNITED STATES
JUDICIAL PANEL ON
MULTIDISTRICT LITIGATION

FOR THE PANEL:

Marcella Lockert Acting Clerk of the Panel

Magcella G. hocken

IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION

MDL No. 3094

SCHEDULE CTO-17 - TAG-ALONG ACTIONS

<u>DIST</u>	<u>DIV.</u>	<u>C.A.NO.</u>	CASE CAPTION		
FLORIDA MIDDLE					
FLM	3	24-00648	Harris v. Novo Nordisk A/S et al		
FLORIDA SO	OUTHERN				
FLS	0	24-61108	Rivera v. Novo Nordisk A/S et al		
GEORGIA S	OUTHERN				
GAS	1	24-00099	Morris v. Novo Nordisk A/S et al		
KENTUCKY	EASTERN				
KYE	5	24-00173	Castle v. Novo Nordisk A/S et al		
NEW YORK	NORTHER	N.			
NYN	1	24-00795	Little v. Eli Lilly and Company		
OHIO SOUT	HERN				
OHS	1	24-00346	Cook v. Novo Nordisk A/S et al		
OHS OHS	3	24–00185 24–00186	McCoy v. Novo Nordisk A/S et al Magee v. Novo Nordisk et al		
TENNESSEE EASTERN					
TNE	3	24-00276	Chudley v. Eli Lilly and Company		
TENNESSEE	E MIDDLE				
TNM	3	24-00770	Hobbs v. Eli Lilly and Company		
TEXAS EAS	TERN				
TXE	1	24-00252	Chesson v. Novo Nordisk A/S et al		
TEXAS SOUTHERN					
TXS	1	24-00096	Camero v. Novo Nordisk A/S et al		

Case: 3:24-cv-00186-WHR-CHG Doc #: 2 Filed: 07/11/24 Page: 3 of 3 PAGEID #: 59 Case MDL No. 3094 Document 232 Filed 07/11/24 Page 3 of 3

TXS	4	24-02406	Bradley v. Novo Nordisk A/S
TEXAS WES	TERN		
TXW	1	24-00707	McClain v. Eli Lilly and Company
TXW	6	24-00343	Gunter v. Novo Nordisk A/S et al